These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 12684131)

  • 1. Challenges and opportunities to the design and implementation of chemoprevention trials for prostate cancer.
    Thompson IM; Basler JA; Leach R; Troyer D; Klein E; Brawley O
    Urol Oncol; 2003; 21(1):73-8. PubMed ID: 12684131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SELECT: the selenium and vitamin E cancer prevention trial.
    Klein EA; Thompson IM; Lippman SM; Goodman PJ; Albanes D; Taylor PR; Coltman C
    Urol Oncol; 2003; 21(1):59-65. PubMed ID: 12684129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design considerations for efficient prostate cancer chemoprevention trials.
    Lee JJ; Lieberman R; Sloan JA; Piantadosi S; Lippman SM
    Urology; 2001 Apr; 57(4 Suppl 1):205-12. PubMed ID: 11295629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer chemoprevention: Strategies for designing efficient clinical trials.
    Lieberman R
    Urology; 2001 Apr; 57(4 Suppl 1):224-9. PubMed ID: 11295633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoprevention of prostate cancer. Focus on key opportunities and clinical trials.
    Leach R; Pollock B; Basler J; Troyer D; Naylor S; Thompson IM
    Urol Clin North Am; 2003 May; 30(2):227-37. PubMed ID: 12735500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The future of prostate cancer prevention.
    Brawley OW; Barnes S; Parnes H
    Ann N Y Acad Sci; 2001 Dec; 952():145-52. PubMed ID: 11795434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opportunities and challenges in incorporating ancillary studies into a cancer prevention randomized clinical trial.
    Goodman PJ; Tangen CM; Darke AK; Arnold KB; Hartline J; Yee M; Anderson K; Caban-Holt A; Christen WG; Cassano PA; Lance P; Klein EA; Crowley JJ; Minasian LM; Meyskens FL
    Trials; 2016 Aug; 17():400. PubMed ID: 27519183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
    Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
    Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is There a Future for Chemoprevention of Prostate Cancer?
    Bosland MC
    Cancer Prev Res (Phila); 2016 Aug; 9(8):642-7. PubMed ID: 27099271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What's new in the field of prostate cancer chemoprevention?
    Mahal K; Hernandez J; Basler JW; Thompson IM
    Curr Oncol Rep; 2004 May; 6(3):237-42. PubMed ID: 15066236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer chemoprevention.
    Sandhu GS; Nepple KG; Tanagho YS; Andriole GL
    Semin Oncol; 2013 Jun; 40(3):276-85. PubMed ID: 23806493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of prostate cancer.
    DePrimo SE; Shinghal R; Vidanes G; Brooks JD
    Hematol Oncol Clin North Am; 2001 Jun; 15(3):445-57. PubMed ID: 11525290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
    Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
    Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamins A and E: further clues for prostate cancer prevention.
    Olson KB; Pienta KJ
    J Natl Cancer Inst; 1998 Mar; 90(6):414-5. PubMed ID: 9521160
    [No Abstract]   [Full Text] [Related]  

  • 16. What's new in the field of prostate cancer chemoprevention?
    Mahal K; Hernandez J; Basler JW; Thompson IM
    Curr Urol Rep; 2005 May; 6(3):177-82. PubMed ID: 15869721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preneoplastic prostate lesions: an opportunity for prostate cancer prevention.
    Nelson WG; De Marzo AM; Deweese TL; Lin X; Brooks JD; Putzi MJ; Nelson CP; Groopman JD; Kensler TW
    Ann N Y Acad Sci; 2001 Dec; 952():135-44. PubMed ID: 11795433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare resources should be targeted to chemoprevention: the argument against.
    Trachtenberg J
    Eur Urol; 1996; 29 Suppl 2():17-8. PubMed ID: 8717455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antioxidants for prostate cancer chemoprevention: challenges and opportunities.
    Thapa D; Ghosh R
    Biochem Pharmacol; 2012 May; 83(10):1319-30. PubMed ID: 22248733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First International Conference on Chemoprevention of Prostate Cancer. Overview consensus statement.
    Thompson IM; Albanes D; Basler JW; Crawford ED; Denis LJ; Djavan B; Fleshner N; Johnson-Pais TL; Klein EA; Kristal AR; Lucia MS; Parnes HL; Piazza GA; Platz EA; Pollock BH; Price DK; Reichardt JK; Tangen CM; Tolcher AW; McMann MC
    J Urol; 2004 Feb; 171(2 Pt 2):S3-4. PubMed ID: 14713744
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.